News | News By Subject | News by Disease News By Date | Search News

Lymphoma News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Pharma Giant AstraZeneca PLC (AZN) Scores Another FDA Breakthrough     8/3/2017
Kite Pharma (KITE) Touts Remissions Up to 56+ Months in Non-Hodgkin Lymphoma Patients on CAR T-Cell Therapy     7/21/2017
Investors Relieved as Seattle Genetics (SGEN) Pulls Out Win for Phase III Lymphoma Trial     6/27/2017
Epizyme (EPZM) Falls as Investors Take in Disappointing Phase II Data     6/16/2017
3 Cancer Biotechs to Watch at ASCO     5/9/2017
Novartis AG (NVS) Remains Hush-Hush About CAR-T Trial But the FDA is Impressed and Thinks It's a Breakthrough     4/20/2017
FDA Calls It! Seattle Genetics (SGEN)' Adcetris is a Breakthrough for Lymphoma     11/14/2016
Takeda (TKPYY), Seattle Genetics (SGEN) Show Off Significant Phase III ALCANZA Data for T-Cell Lymphoma     8/1/2016
Celgene (CELG)'s Revlimid Fails to Extend Survival in Lymphoma Study     7/26/2016
Genentech (RHHBY) Receives a Blow After Lymphoma Drug Flunks Phase III Test     7/19/2016
Genentech (RHHBY)’s Gazyva Meets Primary Endpoint Early in Late-Stage Study     5/27/2016
FDA Lifts Partial Clinical Hold on Medivation (MDVN)'s Pidilizumab     3/9/2016
FDA Green Lights Genentech (RHHBY)'s Gazyva for Patients with Previously Treated Follicular Lymphoma     2/26/2016
Orphan Drug Designation Status for Acerta Pharma Drug Vindicates AstraZeneca PLC (AZN)’s $4 Billion Deal     2/26/2016
Analyst Questions High Cost of T Cell Therapies as Potential Frontline Treatment for Blood Cancers     2/25/2016

News from Around the Web
Why It Feels So Good To Scratch An Itch, Published In Proceedings Of The Entomological Society Of Washington     2/29/2016
Kite Pharma (KITE)'s CEO On Cancer-Killing T-Cells: "This Is A Revolution"     2/29/2016
BioSpace’s Favorite FDA Tricks Or Treats     10/24/2014
Novel Drug Shuts Down Master Protein Key to Lymphoma, Weill Cornell Medical College Study     8/5/2013
New Technique Catalogs Lymphoma-Linked Genetic Variations, Johns Hopkins University School of Medicine Study     12/27/2012
B-Cell Lymphoma: New Research Provides Breakthrough in Understanding Common Cancer, University of Sheffield Study     6/10/2011
"Sniffing Out" Lymphoma Genes by Turning Dogs into Humans, North Carolina State University Study     4/7/2011
Gene Mutation Linked to Deadly Lymphoma, University of Rochester Study     1/3/2011
National Institutes of Health (NIH) Scientists Identify Possible Gene Target for Treating a Form of Lymphoma     12/29/2010
Conjugate Drug Shows Benefit in Lymphoma, University of Texas Study     11/4/2010
Hepatitis B Linked To Lymphoma In National Cancer Institute and Sun Ha Jee of Yonsei University Study     8/4/2010
Vitamin K May Protect Against Developing Non-Hodgkin's Lymphoma, Say Mayo Clinic Researchers     4/21/2010
Seaweed Extract May Hold Promise for Non-Hodgkin's Lymphoma Treatment, The Hashemite University Study     3/11/2010
Approved Lymphoma Drug Shows Promise In Early Tests Against Bone Cancer, University of Rochester Medical Center Study     11/6/2009
Genentech, Inc. (DNA) And Biogen Idec, Inc. (California) (BIIB)'s Rituximab Maintenance Therapy Improves Survival In Patients With Relapsed Follicular Lymphoma, Rabin Medical Center (Beilinson Hospital) Study     2/11/2009

Press Releases
Seattle Genetics (SGEN) Release: FDA Accepts Supplemental Biologics License Application And Grants Priority Review For ADCETRIS (Brentuximab Vedotin) In Cutaneous T-Cell Lymphoma     8/16/2017
TG Therapeutics (TGTX) Announces Successful Outcome From The First Pre-Planned Interim Analysis By Independent DSMB Of The DLBCL Cohort In The UNITY-NHL Phase IIb Trial     8/10/2017
In Race, Kite Pharma (KITE) Slides Head-First to File CAR-T MAA in Europe     7/31/2017
Seattle Genetics (SGEN) Release: Health Canada Approves ADCETRIS (Brentuximab Vedotin) For The Post-ASCT Consolidation Treatment Of Patients With Hodgkin Lymphoma At Increased Risk Of Relapse Or Progression     7/25/2017
The Leukemia & Lymphoma Society Announces Expansion Of Groundbreaking Precision Medicine Approach To Fight Deadly Blood Cancer     7/19/2017
New Evidence Of Sutro Biopharma ADC's Potency In Human Tumor Xenografts     7/17/2017
Oncoceutics Release: Mechanistic Study Uncovers New Utility Of ONC201 Mechanism In Lymphoma     7/14/2017
European Hematology Association: Early Metabolic Response Determination By FDG-PET Allows Substantial Reduction Of Chemotherapy And Its Toxicity In Patients With Advanced Stage Hodgkin Lymphoma: The GHSG HD18 Study     6/26/2017
European Hematology Association: Global Trial Of The Efficacy And Safety Of CTL019 In Adult Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: An Interim Analysis Of The JULIET Study     6/26/2017
TG Therapeutics (TGTX) Recaps Data From Triple Combination Therapy Trials At The 22nd European Hematology Association Annual Congress     6/26/2017
Karyopharm (KPTI) Reports Updated Phase IIb SADAL Data For Selinexor In Diffuse Large B-Cell Lymphoma At The 2017 European Hematology Association Annual Meeting     6/23/2017
Seattle Genetics (SGEN) Submits Supplemental Biologics License Application To FDA For ADCETRIS (Brentuximab Vedotin) In Cutaneous T-Cell Lymphoma     6/20/2017
Celgene (CELG) Release: Updated Data From Phase IIb MAGNIFY Study Of REVLIMID (Lenalidomide) And Rituximab Combination (R2) Show Clinical Activity And Responses In Relapsed/Refractory Follicular And Marginal Zone Lymphoma     6/19/2017
Juno (JUNO) Presents TRANSCEND NHL 001 Trial Data At International Conference On Malignant Lymphoma     6/19/2017
Unum Announces Active Investigational New Drug (IND) Application For ACTR707 In Combination With Rituximab In Patients With Relapsed/Refractory B-Cell Lymphoma     6/19/2017

//-->